BlackRock discloses stake in Mural Oncology

LONDON - Investment management corporation BlackRock (NYSE:BLK), Inc. has reported its position in Mural Oncology plc, a company currently under the spotlight due to takeover rules. As per the latest disclosure on Monday, BlackRock holds interests and short positions that cross the threshold of 1% in the healthcare firm’s securities.

The disclosure, mandated by the Irish Takeover Panel Act and Takeover Rules, indicates that BlackRock owns 284,199 ordinary shares of Mural Oncology, which represents a 1.64% stake in the company. Additionally, BlackRock has cash-settled derivatives amounting to 71,756 shares, translating to a 0.41% short position in the company.

The report, submitted to the Regulatory Information Service on May 12, 2025, is part of the standard regulatory requirements for entities holding significant interests in companies involved in takeover situations. BlackRock’s disclosure does not suggest any immediate intention to influence control or management of Mural Oncology but provides transparency regarding its investment position.

The dealings leading to this disclosure took place on May 9, 2025, with no other dealings reported across other classes of relevant securities. Moreover, there was a transfer out of 1,044 ordinary shares, as noted in the disclosure form. No supplemental form 8 was attached, indicating no additional stock-settled derivatives transactions or other dealings occurred.

BlackRock, as a global investment manager, routinely discloses such positions in compliance with market regulations. This disclosure does not necessarily signal a strategic move but is rather a statement of investment holdings as required by law for entities with over a 1% interest in a company’s relevant securities.

The information is based on a press release statement and offers a glimpse into the investment landscape surrounding Mural Oncology plc, without suggesting any broader market implications or trends.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.